Clinical trials & human evidence

What the actual human studies show

TB-500 stands out from most gray-market peptides because thymosin beta-4 has been through real human trials, run mainly by RegeneRx and by ReGenTree LLC, the sponsor named on the two dry-eye phase 3 trials of 601 and 700 patients. But "real trials" is not the same as "proven": every one of those pivotal trials has now reported, and none produced a positive primary endpoint, and none of them tested the injected use that drives community demand.

This unit places the evidence on a ladder, walks the human safety and dry-eye data, and is honest about what those completed trials actually returned.